These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11833485)

  • 1. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation.
    Krivoy N; Hoffer E; Tabak A; Elhasid R; Arush MW; Stein J; Yaniv I; Rowe JM
    Pediatr Hematol Oncol; 2002; 19(1):31-7. PubMed ID: 11833485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation.
    Hoffer E; Akria L; Tabak A; Scherb I; Rowe JM; Krivoy N
    Ther Drug Monit; 2004 Jun; 26(3):331-5. PubMed ID: 15167637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
    Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
    Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
    Vassal G; Koscielny S; Challine D; Valteau-Couanet D; Boland I; Deroussent A; Lemerle J; Gouyette A; Hartmann O
    Cancer Chemother Pharmacol; 1996; 37(3):247-53. PubMed ID: 8529285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
    Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ
    Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
    Grochow LB
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of busulfan area under the curve: estimation by a single measurement.
    Tabak A; Hoffer E; Rowe JM; Krivoy N
    Ther Drug Monit; 2001 Oct; 23(5):526-8. PubMed ID: 11591898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
    Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
    J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
    Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
    Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
    Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
    Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
    Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.